US Senate Judiciary Committee unanimously votes to send bipartisan patent reform legislation to full Senate

4 February 2011

A unanimous vote by the USA’s Senate Judiciary Committee yesterday sent comprehensive patent reform legislation to the full Senate for the third time since 2008. The Patent Reform Act is authored by Senators Patrick Leahy (Democrat, Vermont), Orrin Hatch (Republican, Utah), and Chuck Grassley (Rep, Iowa).

Congressional efforts to reform the nation’s patent system first began in 2005. The legislation approved by the Judiciary Committee on Thursday is the product of years of work and compromise. Enactment of the Patent Reform Act of 2011 will make the first significant changes to the patent system in nearly 60 years, and will create and protect American jobs without adding to the nation’s deficit.

The Patent Reform Act makes changes to inter partes review, Patent and Trademark Office funding, and supplemental examinations. The legislation will also transition the nation’s patent system to a first-inventor-to-file system, create a first-window post-grant review process, provide certainty in damages calculations and findings of willful infringement, and includes important provisions to improve patent quality. The bill is based largely on a bill introduced in the 109th Congress by House Judiciary Committee Chairman Lamar Smith (Rep, Texas) and Congressman Howard Berman (Dem, California).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical